Snapshot · Zoetis Inc. (ZTS)

Data as of 2026-10-18T23:14:50.550Z

Fundamentals check

Market cap

$32.8B

P/E (TTM)

13.0

Gross margin

70.9%

Net margin

27.5%

ROE

69.3%

R&D / revenue

7.6%

Dividend yield

2.6%

FCF yield

7.2%

Latest dividend: $0.53/share (ex-date 2026-10-30, quarterly)

Summary

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.

How it makes money

Revenue mix, latest fiscal year

• Horses67.8%
• Cattle16.1%
• Swine5%
• Poultry4.7%
• Dogs and Cats3.3%
• Fish3.1%

Recent Events

• 2026-10-17T03:25:28.000Zneutral

  8,293 Zoetis Inc. $ZTS Shares Sold by Banque Pictet & Cie SA

  基金减持消息，可能与投资组合调整相关，具体市场反应尚未确定。

  Source: defenseworld.net

• 2026-10-15T00:00:00.000Zpositive

  Price move: ZTS rose 4.2%

  ZTS 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-10-13T07:30:00.000Zneutral

  Zoetis Appoints Iris Knobloch to its Board of Directors

  恰逢董事会变动消息，可能对公司治理预期产生影响，具体股价影响尚不明确。

  Source: businesswire.com

• 2026-10-09T21:15:05.000Zpositive

  Zoetis (ZTS) Outpaces Stock Market Gains: What You Should Know

  股价在最新交易日走强，可能与公司基本面与市场情绪相关，具体因果尚不确认。

  Source: Zacks Investment Research

• 2026-10-08T16:15:00.000Zpositive

  Zoetis Declares Fourth Quarter 2026 Dividend

  宣布分红，可能对股东回报预期有正面作用，具体股价影响尚不确定。

  Source: businesswire.com

• 2026-09-24T07:30:00.000Zneutral

  Zoetis to Host Webcast and Conference Call on Third Quarter 2026 Financial Results

  将召开财报电话会，可能为后续结果提供沟通，影响尚不确定。

  Source: businesswire.com

• 2026-08-19T00:00:00.000Zpositive

  Price move: ZTS rose 3.7%

  ZTS 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-08-07T00:00:00.000Znegative

  Price move: ZTS fell 6.0%

  ZTS 在这段行情中出现明显波动，恰逢异常的价格变动，但此处没有可关联到的具体新闻事件。

• 2026-08-06T00:00:00.000Zneutral

  ZTS filed 8-K

  可能与公司更新相关，具体影响尚不确定。

  Source: SEC EDGAR

Analyst view

Avg price target $86.17 from 6 analysts (last quarter)

Insider & Congress activity

订阅每日简报

每个交易日开盘/收盘后，中文市场简报直达邮箱。免费，随时退订。

本内容仅为信息整理，不构成任何投资建议。